X0306 4 2021-06-14 0 0001580063 PROGENITY, INC. PROG 0001728001 Athyrium Capital Management, LP 505 FIFTH AVENUE, FLOOR 18 NEW YORK NY 10017 0 0 1 0 0001394967 Ferrell Jeffrey 505 FIFTH AVENUE, FLOOR 18 NEW YORK NY 10017 1 0 1 0 0001815216 Athyrium Capital Holdings, LLC 505 FIFTH AVENUE, FLOOR 18 NEW YORK NY 10017 0 0 1 0 0001815225 Athyrium Funds GP Holdings LLC 505 FIFTH AVENUE, FLOOR 18 NEW YORK NY 10017 0 0 1 0 0001815501 NB Alternatives Holdings LLC 1290 AVENUE OF THE AMERICAS, 42ND FLOOR NEW YORK NY 10104 0 0 1 0 0001815484 Athyrium Opportunities Advisers LLC 1290 AVENUE OF THE AMERICAS, 42ND FLOOR NEW YORK NY 10104 0 0 1 0 0001835266 Athyrium Opportunities III Acquisition LP 505 FIFTH AVENUE, FLOOR 18 NEW YORK NY 10017 0 0 1 0 0001469000 NB Alternatives Advisers LLC 325 N. SAINT PAUL STREET, SUITE 4900 DALLAS TX 75201 0 0 1 0 0001815407 NB Alternatives GP Holdings LLC 325 N. SAINT PAUL STREET, SUITE 4900 DALLAS TX 75201 0 0 1 0 Common Stock 2021-06-14 4 P 0 8097166 2.47 A 36396907 I See footnotes Warrant 2.84 2021-06-14 4 P 0 8097166 2.47 A 2021-06-14 2026-06-14 Common Stock 8097166 8097166 I See footnotes The shares of the Issuer's common stock and the Warrant were purchased for $2.47 per unit, with each unit consisting of one share of the Issuer's common stock and the right to buy an additional share of the Issuer's common stock for the exercise price specified in the Warrant. The 8,097,166 shares of the Issuer's common stock and the Warrant are directly owned by Athyrium Opportunities III Acquisition 2 LP. Athyrium Opportunities Associates III GP LLC is the general partner of Athyrium Opportunities Associates III LP, which is the general partner of Athyrium Opportunities III Acquisition 2 LP. Athyrium Funds GP Holdings, LLC is the managing member of Athyrium Opportunities Associates III GP LLC. Jeffrey Ferrell is the managing member of Athyrium Funds GP Holdings, LLC and the President of Athyrium Opportunities Associates III GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The Warrant represents a right to buy 8,097,166 shares of the Issuer's common stock at an exercise price of $2.84 per share. The Warrant is exercisable at any time and from time to time prior to June 14, 2026. Because no more than 10 reporting persons can file any one Form 4 through the Securities and Exchange Commission's EDGAR system, certain affiliates of the Reporting Persons have filed a separate Form 4. /s/ Athyrium Capital Management, LP, by Jeffrey A. Ferrell, President 2021-06-14 /s/ Jeffrey A. Ferrell 2021-06-14 /s/ Athyrium Capital Holdings, LLC, by Jeffrey A. Ferrell, Managing Member 2021-06-14 /s/ Athyrium Funds GP Holdings LLC, by Jeffrey A. Ferrell, Managing Member 2021-06-14 /s/ Athyrium Opportunities Advisers LLC, by Christian Neira, Authorized Signatory 2021-06-14 /s/ NB Alternatives Advisers LLC, by Christian Neira, Authorized Signatory 2021-06-14 /s/ NB Alternatives GP Holdings LLC, by Christian Neira, Authorized Signatory 2021-06-14 /s/ NB Alternatives Holdings LLC, by Christian Neira, Authorized Signatory 2021-06-14 /s/ Athyrium Opportunities III Acquisition LP, by Athyrium Opportunities Associates III LP, its general partner, by Athyrium Opportunities Associates III GP LLC, its general partner, by Andrew Hyman, Senior Vice President, Secretary 2021-06-14